Metabolic improvement with short-term, glucagon-like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.

Bojer AS, Sørensen MH, Bjerre J, Gaede P, Vejlstrup N, Madsen PL

Diabetes, obesity & metabolism26 Jul 2021Cited by 10 (Europe PMC)

PMID34189832DOI10.1111/dom.14480PepBankPUB-34189832

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and diastolic dysfunction, liraglutide did not change the early peak filling rate at rest versus placebo.
In plain wordsIn adults with type 2 diabetes and stiff heart muscle, liraglutide did not improve how fast the heart fills at rest.
Peptide
Liraglutide
Outcome
No significant changeEarly peak filling rate at rest
Study
n = 40
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg/day · subcutaneous · 18 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide did not change ePFR at rest (-24 ± 60 vs. -6 ± 46 mL/s), during stress (2 ± 58 vs. -2 ± 38 mL/s), or the changes from rest to stress (12.9 ± 72.5 vs. 4.7 ± 104.0; all P > .05).
2 context sentences(design, population, supporting numbers)
Summary · context
Primary outcomes were improved left ventricle filling (the early peak filling rate [ePFR]) and left atrium ease of emptying (the passive emptying fraction [LA_PEF ]), assessed by cardiac magnetic resonance imaging at rest and during chronotropic stress.
Summary · context
Forty patients were randomized to liraglutide subcutaneously 1.8 mg/day (n = 20) or placebo (n = 20).
Report a problemFND-3418983203
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and diastolic dysfunction, liraglutide did not change the early peak filling rate during stress versus placebo.
In plain wordsIn adults with type 2 diabetes and stiff heart muscle, liraglutide did not improve how fast the heart fills under stress.
Peptide
Liraglutide
Outcome
No significant changeEarly peak filling rate during stress
Study
n = 40
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg/day · subcutaneous · 18 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide did not change ePFR at rest (-24 ± 60 vs. -6 ± 46 mL/s), during stress (2 ± 58 vs. -2 ± 38 mL/s), or the changes from rest to stress (12.9 ± 72.5 vs. 4.7 ± 104.0; all P > .05).
2 context sentences(design, population, supporting numbers)
Summary · context
Primary outcomes were improved left ventricle filling (the early peak filling rate [ePFR]) and left atrium ease of emptying (the passive emptying fraction [LA_PEF ]), assessed by cardiac magnetic resonance imaging at rest and during chronotropic stress.
Summary · context
Forty patients were randomized to liraglutide subcutaneously 1.8 mg/day (n = 20) or placebo (n = 20).
Report a problemFND-3418983204
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and diastolic dysfunction, liraglutide did not change the rest-to-stress change in early peak filling rate versus placebo.
In plain wordsIn adults with type 2 diabetes and stiff heart muscle, liraglutide did not change how heart filling shifted from rest to stress.
Peptide
Liraglutide
Outcome
No significant changeEarly peak filling rate, change from rest to stress
Study
n = 40
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg/day · subcutaneous · 18 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide did not change ePFR at rest (-24 ± 60 vs. -6 ± 46 mL/s), during stress (2 ± 58 vs. -2 ± 38 mL/s), or the changes from rest to stress (12.9 ± 72.5 vs. 4.7 ± 104.0; all P > .05).
2 context sentences(design, population, supporting numbers)
Summary · context
Primary outcomes were improved left ventricle filling (the early peak filling rate [ePFR]) and left atrium ease of emptying (the passive emptying fraction [LA_PEF ]), assessed by cardiac magnetic resonance imaging at rest and during chronotropic stress.
Summary · context
Forty patients were randomized to liraglutide subcutaneously 1.8 mg/day (n = 20) or placebo (n = 20).
Report a problemFND-3418983205
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and diastolic dysfunction, the left atrial passive emptying fraction during stress decreased with liraglutide versus placebo (P = .049).
In plain wordsIn adults with type 2 diabetes and stiff heart muscle, how easily the upper heart chamber empties was lower with liraglutide under stress.
Peptide
Liraglutide
Outcome
DecreaseLeft atrial passive emptying fraction during stress
Study
n = 40
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg/day · subcutaneous · 18 weeksAs given in this study (human).
Source sentences
Summary
LA_PEF decreased with liraglutide during stress (-3.1% [-9.0%, 1.1%] vs. 1.0% [-2.9%, 6.1%]; P = .049), but no changes were evident at rest (-4.3% [-7.9%, 1.9%] vs. -0.6% [-3.1%, 2.2%]; P = .19), or for the changes from rest to stress (-1.7 ± 8.4 vs. 0.8 ± 8.2; P = .4).
2 context sentences(design, population, supporting numbers)
Summary · context
Primary outcomes were improved left ventricle filling (the early peak filling rate [ePFR]) and left atrium ease of emptying (the passive emptying fraction [LA_PEF ]), assessed by cardiac magnetic resonance imaging at rest and during chronotropic stress.
Summary · context
Forty patients were randomized to liraglutide subcutaneously 1.8 mg/day (n = 20) or placebo (n = 20).
Report a problemFND-3418983206
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and diastolic dysfunction, the left atrial passive emptying fraction at rest did not change with liraglutide versus placebo (P = .19).
In plain wordsIn adults with type 2 diabetes and stiff heart muscle, liraglutide did not change how the upper heart chamber emptied at rest.
Peptide
Liraglutide
Outcome
No significant changeLeft atrial passive emptying fraction at rest
Study
n = 40
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg/day · subcutaneous · 18 weeksAs given in this study (human).
Source sentences
Summary
LA_PEF decreased with liraglutide during stress (-3.1% [-9.0%, 1.1%] vs. 1.0% [-2.9%, 6.1%]; P = .049), but no changes were evident at rest (-4.3% [-7.9%, 1.9%] vs. -0.6% [-3.1%, 2.2%]; P = .19), or for the changes from rest to stress (-1.7 ± 8.4 vs. 0.8 ± 8.2; P = .4).
2 context sentences(design, population, supporting numbers)
Summary · context
Primary outcomes were improved left ventricle filling (the early peak filling rate [ePFR]) and left atrium ease of emptying (the passive emptying fraction [LA_PEF ]), assessed by cardiac magnetic resonance imaging at rest and during chronotropic stress.
Summary · context
Forty patients were randomized to liraglutide subcutaneously 1.8 mg/day (n = 20) or placebo (n = 20).
Report a problemFND-3418983207
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and diastolic dysfunction, the rest-to-stress change in left atrial passive emptying fraction did not differ with liraglutide versus placebo (P = .4).
In plain wordsIn adults with type 2 diabetes and stiff heart muscle, liraglutide did not change how upper heart chamber emptying shifted from rest to stress.
Peptide
Liraglutide
Outcome
No significant changeLeft atrial passive emptying fraction, change from rest to stress
Study
n = 40
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg/day · subcutaneous · 18 weeksAs given in this study (human).
Source sentences
Summary
LA_PEF decreased with liraglutide during stress (-3.1% [-9.0%, 1.1%] vs. 1.0% [-2.9%, 6.1%]; P = .049), but no changes were evident at rest (-4.3% [-7.9%, 1.9%] vs. -0.6% [-3.1%, 2.2%]; P = .19), or for the changes from rest to stress (-1.7 ± 8.4 vs. 0.8 ± 8.2; P = .4).
2 context sentences(design, population, supporting numbers)
Summary · context
Primary outcomes were improved left ventricle filling (the early peak filling rate [ePFR]) and left atrium ease of emptying (the passive emptying fraction [LA_PEF ]), assessed by cardiac magnetic resonance imaging at rest and during chronotropic stress.
Summary · context
Forty patients were randomized to liraglutide subcutaneously 1.8 mg/day (n = 20) or placebo (n = 20).
Report a problemFND-3418983208
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and diastolic dysfunction, secondary cardiac outcomes were unchanged by liraglutide.
In plain wordsIn adults with type 2 diabetes and stiff heart muscle, liraglutide did not change the other heart measures tested.
Peptide
Liraglutide
Outcome
No significant changeSecondary cardiac outcomes
Study
n = 40
Comparator
Placebo
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg/day · subcutaneous · 18 weeksAs given in this study (human).
Source sentences
Summary
Secondary outcomes were unchanged by liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes included left ventricular and left atrial volumes and systolic function, measures of aortic stiffness and echocardiographic diastolic variables.
Summary · context
Forty patients were randomized to liraglutide subcutaneously 1.8 mg/day (n = 20) or placebo (n = 20).
Report a problemFND-3418983209
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and diastolic dysfunction, 18 weeks of liraglutide reduced HbA1c versus placebo.
In plain wordsIn adults with type 2 diabetes and stiff heart muscle, liraglutide lowered HbA1c more than placebo over 18 weeks.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change
Study
n = 40
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · subcutaneous · 18 weeksAs given in this study (human).
Measurements
HbA1c change
−0.47%
liraglutide vs placebo
Source sentences
Summary
Liraglutide reduced HbA1c (-0.47%, 95% CI [-0.88% to -0.06%] [-5.1, 95% CI {-9.7 to -0.62} mmol/mol]) and weight (-2.9, 95% CI [-4.6 to -1.2] kg); both P < .03.
2 context sentences(design, population, supporting numbers)
Summary · context
An investigator-initiated, double-blind, randomized, placebo-controlled trial on the effect of 18 weeks of treatment with liraglutide on diastolic function was assessed in patients with type 2 diabetes with signs of diastolic dysfunction (echo-Doppler determined E/e' ≥ 9 and/or lateral e' ≤ 10 cm/s).
Summary · context
Forty patients were randomized to liraglutide subcutaneously 1.8 mg/day (n = 20) or placebo (n = 20).
Report a problemFND-3418983201
09HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and diastolic dysfunction, 18 weeks of liraglutide reduced body weight versus placebo.
In plain wordsIn adults with type 2 diabetes and stiff heart muscle, liraglutide reduced body weight more than placebo over 18 weeks.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 40
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg/day · subcutaneous · 18 weeksAs given in this study (human).
Measurements
weight change
−2.9 kg
liraglutide vs placebo
Source sentences
Summary
Liraglutide reduced HbA1c (-0.47%, 95% CI [-0.88% to -0.06%] [-5.1, 95% CI {-9.7 to -0.62} mmol/mol]) and weight (-2.9, 95% CI [-4.6 to -1.2] kg); both P < .03.
2 context sentences(design, population, supporting numbers)
Summary · context
An investigator-initiated, double-blind, randomized, placebo-controlled trial on the effect of 18 weeks of treatment with liraglutide on diastolic function was assessed in patients with type 2 diabetes with signs of diastolic dysfunction (echo-Doppler determined E/e' ≥ 9 and/or lateral e' ≤ 10 cm/s).
Summary · context
Forty patients were randomized to liraglutide subcutaneously 1.8 mg/day (n = 20) or placebo (n = 20).
Report a problemFND-3418983202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.